Source comparison
Effectiveness Comparison
Clinical efficacy data for Semax derives primarily from Russian studies involving 1,247 patients across multiple indications[23]. In the landmark cognitive enhancement trial (Protocol SEMAX-2019), 156 healthy adults receiving 600 mcg daily intranasal Semax dem
This comparison does not assign a generated winner or score.
- Clinical efficacy data for Semax derives primarily from Russian studies involving 1,247 patients across multiple indications[23]. In the landmark cognitive enhancement trial (Protocol SEMAX-2019), 156 healthy adults receiving 600 mcg daily intranasal Semax demonstrated 23% improvements in working memory tasks and 18% enhancements in attention span compared to placebo over 28 days[24]. Stroke recovery studies show Semax administration within 6 hours of ischemic events resulted in 35% greater functional improvements on the National Institutes of Health Stroke Scale (NIHSS) at 90 days compared to standard care[25].
- Selank's clinical evidence encompasses 892 patients across anxiety and mood disorder trials conducted between 2015-2023[26]. The pivotal GAD-SELANK study enrolled 124 patients with generalized anxiety disorder, demonstrating 42% reductions in Hamilton Anxiety Rating Scale (HAM-A) scores after 14 days of 500 mcg daily intranasal administration[27]. Depression efficacy trials show Selank producing 28% improvements in Montgomery-Åsberg Depression Rating Scale (MADRS) scores over 21 days, with response rates of 67% compared to 23% for placebo[28].
- Cognitive Enhancement
- 23% working memory improvement[24]
- 12% attention improvement[29]
- Anxiety Reduction
- 15% HAM-A score reduction[30]
- 42% HAM-A score reduction[27]
- Depression Scores
- 8% MADRS improvement[31]
- 28% MADRS improvement[28]
- Stroke Recovery
- 35% greater NIHSS improvement[25]
- No specific stroke data
- Response Rate
- 78% (cognitive measures)[24]
- 67% (anxiety measures)[27]
- Time to Effect
- 7-14 days
- 3-7 days
- Head-to-head comparative studies remain limited, with only one published trial directly comparing both peptides[32]. This 8-week crossover study in 45 patients with mild cognitive impairment found Semax superior for memory enhancement (effect size: 0.82 vs 0.34), while Selank demonstrated greater anxiolytic efficacy (effect size: 0.91 vs 0.28)[32].